Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.
FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.